Alectinib Superior to Crizotinib for ALK+ NSCLC.
Sign Up to like & getrecommendations! Published in 2017 at "Cancer discovery"
DOI: 10.1158/2159-8290.cd-nb2017-090
Abstract: Findings from the global phase III ALEX trial unequivocally show that alectinib is superior to crizotinib as first-line therapy for ALK+ non-small cell lung cancer. Alectinib more than doubled progression-free survival, significantly reduced the incidence… read more here.
Keywords: crizotinib alk; alk nsclc; alectinib superior; superior crizotinib ... See more keywords